Cargando…

Blood-Derived Systemic Inflammation Markers and Risk of Nodal Failure in Stage Ia Non-Small Cell Lung Cancer: A Multicentric Study

Background: Unexpected spread to regional lymph nodes can be found in up to 10% of patients with early stage non-small cell lung cancer (NSCLC), thereby affecting both prognosis and treatment. Given the known relation between systemic inflammation and tumor progression, we sought to evaluate whether...

Descripción completa

Detalles Bibliográficos
Autores principales: Tacconi, Federico, Mangiameli, Giuseppe, Voulaz, Emanuele, Patirelis, Alexandro, Carlea, Federica, Rocca, Eleonora La, Tamburrini, Alessandro, Vanni, Gianluca, Ambrogi, Vincenzo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10419646/
https://www.ncbi.nlm.nih.gov/pubmed/37568316
http://dx.doi.org/10.3390/jcm12154912
_version_ 1785088575599017984
author Tacconi, Federico
Mangiameli, Giuseppe
Voulaz, Emanuele
Patirelis, Alexandro
Carlea, Federica
Rocca, Eleonora La
Tamburrini, Alessandro
Vanni, Gianluca
Ambrogi, Vincenzo
author_facet Tacconi, Federico
Mangiameli, Giuseppe
Voulaz, Emanuele
Patirelis, Alexandro
Carlea, Federica
Rocca, Eleonora La
Tamburrini, Alessandro
Vanni, Gianluca
Ambrogi, Vincenzo
author_sort Tacconi, Federico
collection PubMed
description Background: Unexpected spread to regional lymph nodes can be found in up to 10% of patients with early stage non-small cell lung cancer (NSCLC), thereby affecting both prognosis and treatment. Given the known relation between systemic inflammation and tumor progression, we sought to evaluate whether blood-derived systemic inflammation markers might help to the predict nodal outcome in patients with stage Ia NSCLC. Methods: Preoperative levels of neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and systemic inflammation score (SII, platelets × NLR) were collected from 368 patients who underwent curative lung resection for NSCLC. After categorization, inflammatory markers were subjected to logistic regression and time-event analysis in order to find associations with occult nodal spread and postoperative nodal recurrence. Results: No inflammation marker was associated with the risk of occult nodal spread. SII showed a marginal effect on early nodal recurrence at a quasi-significant level (p = 0.065). However, patients with T1c tumors and elevated PLR and/or SII had significantly shorter times to nodal recurrence compared to T1a/T1b patients (p = 0.001), while patients with T1c and normal PLR/SII did not (p = 0.128). Conclusions: blood-derived inflammation markers had no value in the preoperative prediction of nodal status. Nevertheless, our results might suggest a modulating effect of platelet-derived inflammation markers on nodal progression after the resection of tumors larger than 2 cm.
format Online
Article
Text
id pubmed-10419646
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-104196462023-08-12 Blood-Derived Systemic Inflammation Markers and Risk of Nodal Failure in Stage Ia Non-Small Cell Lung Cancer: A Multicentric Study Tacconi, Federico Mangiameli, Giuseppe Voulaz, Emanuele Patirelis, Alexandro Carlea, Federica Rocca, Eleonora La Tamburrini, Alessandro Vanni, Gianluca Ambrogi, Vincenzo J Clin Med Article Background: Unexpected spread to regional lymph nodes can be found in up to 10% of patients with early stage non-small cell lung cancer (NSCLC), thereby affecting both prognosis and treatment. Given the known relation between systemic inflammation and tumor progression, we sought to evaluate whether blood-derived systemic inflammation markers might help to the predict nodal outcome in patients with stage Ia NSCLC. Methods: Preoperative levels of neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and systemic inflammation score (SII, platelets × NLR) were collected from 368 patients who underwent curative lung resection for NSCLC. After categorization, inflammatory markers were subjected to logistic regression and time-event analysis in order to find associations with occult nodal spread and postoperative nodal recurrence. Results: No inflammation marker was associated with the risk of occult nodal spread. SII showed a marginal effect on early nodal recurrence at a quasi-significant level (p = 0.065). However, patients with T1c tumors and elevated PLR and/or SII had significantly shorter times to nodal recurrence compared to T1a/T1b patients (p = 0.001), while patients with T1c and normal PLR/SII did not (p = 0.128). Conclusions: blood-derived inflammation markers had no value in the preoperative prediction of nodal status. Nevertheless, our results might suggest a modulating effect of platelet-derived inflammation markers on nodal progression after the resection of tumors larger than 2 cm. MDPI 2023-07-26 /pmc/articles/PMC10419646/ /pubmed/37568316 http://dx.doi.org/10.3390/jcm12154912 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Tacconi, Federico
Mangiameli, Giuseppe
Voulaz, Emanuele
Patirelis, Alexandro
Carlea, Federica
Rocca, Eleonora La
Tamburrini, Alessandro
Vanni, Gianluca
Ambrogi, Vincenzo
Blood-Derived Systemic Inflammation Markers and Risk of Nodal Failure in Stage Ia Non-Small Cell Lung Cancer: A Multicentric Study
title Blood-Derived Systemic Inflammation Markers and Risk of Nodal Failure in Stage Ia Non-Small Cell Lung Cancer: A Multicentric Study
title_full Blood-Derived Systemic Inflammation Markers and Risk of Nodal Failure in Stage Ia Non-Small Cell Lung Cancer: A Multicentric Study
title_fullStr Blood-Derived Systemic Inflammation Markers and Risk of Nodal Failure in Stage Ia Non-Small Cell Lung Cancer: A Multicentric Study
title_full_unstemmed Blood-Derived Systemic Inflammation Markers and Risk of Nodal Failure in Stage Ia Non-Small Cell Lung Cancer: A Multicentric Study
title_short Blood-Derived Systemic Inflammation Markers and Risk of Nodal Failure in Stage Ia Non-Small Cell Lung Cancer: A Multicentric Study
title_sort blood-derived systemic inflammation markers and risk of nodal failure in stage ia non-small cell lung cancer: a multicentric study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10419646/
https://www.ncbi.nlm.nih.gov/pubmed/37568316
http://dx.doi.org/10.3390/jcm12154912
work_keys_str_mv AT tacconifederico bloodderivedsystemicinflammationmarkersandriskofnodalfailureinstageianonsmallcelllungcanceramulticentricstudy
AT mangiameligiuseppe bloodderivedsystemicinflammationmarkersandriskofnodalfailureinstageianonsmallcelllungcanceramulticentricstudy
AT voulazemanuele bloodderivedsystemicinflammationmarkersandriskofnodalfailureinstageianonsmallcelllungcanceramulticentricstudy
AT patirelisalexandro bloodderivedsystemicinflammationmarkersandriskofnodalfailureinstageianonsmallcelllungcanceramulticentricstudy
AT carleafederica bloodderivedsystemicinflammationmarkersandriskofnodalfailureinstageianonsmallcelllungcanceramulticentricstudy
AT roccaeleonorala bloodderivedsystemicinflammationmarkersandriskofnodalfailureinstageianonsmallcelllungcanceramulticentricstudy
AT tamburrinialessandro bloodderivedsystemicinflammationmarkersandriskofnodalfailureinstageianonsmallcelllungcanceramulticentricstudy
AT vannigianluca bloodderivedsystemicinflammationmarkersandriskofnodalfailureinstageianonsmallcelllungcanceramulticentricstudy
AT ambrogivincenzo bloodderivedsystemicinflammationmarkersandriskofnodalfailureinstageianonsmallcelllungcanceramulticentricstudy